Sentences with phrase «increased financial risk»

This trend is placing insured drivers at an increased financial risk in the case of a collision, said the research.

Unfortunately, the Commission has decided to block all start - ups from the funding and increased the financial risk for the companies by cutting the pre-funding.

AVGR doesn't pose an increased financial risk either.

Unfortunately, by its nature, this increases their exposure to unsecured lending, so this new development (along with more debt) has generally increased financial risk in the sector.

«But reforms could also spur increased financial risk - taking and, in some scenarios, could raise leverage from already - elevated levels.»

Standard & Poor's downgraded China's credit rating from AA - to A + in September, citing increased financial risks in the country.

Taking cash out increases your mortgage debt and consequently increases your financial risk.

Again, anytime you convert unsecured debt to secured, you increase your financial risk.

Since the out - of - pocket maximum may be the only thing standing between you and absolute financial ruin if you develop a costly health condition, choosing to get care outside protecting that out - of - pocket maximum will increase your financial risk.

Not exact matches

The minutes of the Fed's June meeting noted that «some participants suggested that increased risk tolerance among investors might be contributing to elevated asset prices more broadly; a few participants expressed concern that subdued market volatility, coupled with a low equity premium, could lead to a build - up of risks to financial stability.»

Sen. Elizabeth Warren, a Massachusetts Democrat who led the progressive opposition to the bill, which she nicknamed the «Bank Lobbyist Act,» argued it will increase risk in the financial system and make another devastating economic crisis more likely.

Important factors that could cause actual results to differ materially from those reflected in such forward - looking statements and that should be considered in evaluating our outlook include, but are not limited to, the following: 1) our ability to continue to grow our business and execute our growth strategy, including the timing, execution, and profitability of new and maturing programs; 2) our ability to perform our obligations under our new and maturing commercial, business aircraft, and military development programs, and the related recurring production; 3) our ability to accurately estimate and manage performance, cost, and revenue under our contracts, including our ability to achieve certain cost reductions with respect to the B787 program; 4) margin pressures and the potential for additional forward losses on new and maturing programs; 5) our ability to accommodate, and the cost of accommodating, announced increases in the build rates of certain aircraft; 6) the effect on aircraft demand and build rates of changing customer preferences for business aircraft, including the effect of global economic conditions on the business aircraft market and expanding conflicts or political unrest in the Middle East or Asia; 7) customer cancellations or deferrals as a result of global economic uncertainty or otherwise; 8) the effect of economic conditions in the industries and markets in which we operate in the U.S. and globally and any changes therein, including fluctuations in foreign currency exchange rates; 9) the success and timely execution of key milestones such as the receipt of necessary regulatory approvals, including our ability to obtain in a timely fashion any required regulatory or other third party approvals for the consummation of our announced acquisition of Asco, and customer adherence to their announced schedules; 10) our ability to successfully negotiate, or re-negotiate, future pricing under our supply agreements with Boeing and our other customers; 11) our ability to enter into profitable supply arrangements with additional customers; 12) the ability of all parties to satisfy their performance requirements under existing supply contracts with our two major customers, Boeing and Airbus, and other customers, and the risk of nonpayment by such customers; 13) any adverse impact on Boeing's and Airbus» production of aircraft resulting from cancellations, deferrals, or reduced orders by their customers or from labor disputes, domestic or international hostilities, or acts of terrorism; 14) any adverse impact on the demand for air travel or our operations from the outbreak of diseases or epidemic or pandemic outbreaks; 15) our ability to avoid or recover from cyber-based or other security attacks, information technology failures, or other disruptions; 16) returns on pension plan assets and the impact of future discount rate changes on pension obligations; 17) our ability to borrow additional funds or refinance debt, including our ability to obtain the debt to finance the purchase price for our announced acquisition of Asco on favorable terms or at all; 18) competition from commercial aerospace original equipment manufacturers and other aerostructures suppliers; 19) the effect of governmental laws, such as U.S. export control laws and U.S. and foreign anti-bribery laws such as the Foreign Corrupt Practices Act and the United Kingdom Bribery Act, and environmental laws and agency regulations, both in the U.S. and abroad; 20) the effect of changes in tax law, such as the effect of The Tax Cuts and Jobs Act (the «TCJA») that was enacted on December 22, 2017, and changes to the interpretations of or guidance related thereto, and the Company's ability to accurately calculate and estimate the effect of such changes; 21) any reduction in our credit ratings; 22) our dependence on our suppliers, as well as the cost and availability of raw materials and purchased components; 23) our ability to recruit and retain a critical mass of highly - skilled employees and our relationships with the unions representing many of our employees; 24) spending by the U.S. and other governments on defense; 25) the possibility that our cash flows and our credit facility may not be adequate for our additional capital needs or for payment of interest on, and principal of, our indebtedness; 26) our exposure under our revolving credit facility to higher interest payments should interest rates increase substantially; 27) the effectiveness of any interest rate hedging programs; 28) the effectiveness of our internal control over financial reporting; 29) the outcome or impact of ongoing or future litigation, claims, and regulatory actions; 30) exposure to potential product liability and warranty claims; 31) our ability to effectively assess, manage and integrate acquisitions that we pursue, including our ability to successfully integrate the Asco business and generate synergies and other cost savings; 32) our ability to consummate our announced acquisition of Asco in a timely matter while avoiding any unexpected costs, charges, expenses, adverse changes to business relationships and other business disruptions for ourselves and Asco as a result of the acquisition; 33) our ability to continue selling certain receivables through our supplier financing program; 34) the risks of doing business internationally, including fluctuations in foreign current exchange rates, impositions of tariffs or embargoes, compliance with foreign laws, and domestic and foreign government policies; and 35) our ability to complete the proposed accelerated stock repurchase plan, among other things.

Thus, anything you can do to reduce the risk and / or increase the reward will improve the likelihood of getting a deal done and enhance the financial terms for the funds.

In the Minutes from the January FOMC meeting, the Federal Reserve addressed the financial situation, and noted that the increasing role of bond and loan mutual funds could pose a liquidity risk if everyone tries to get out of the market at the same time.

The global economy is set for one of its best years since the financial crisis, but recession risks are increasing, said UBS Chairman Axel Weber.

These risks and uncertainties include, among others: the unfavorable outcome of litigation, including so - called «Paragraph IV» litigation and other patent litigation, related to any of our products or products using our proprietary technologies, which may lead to competition from generic drug manufacturers; data from clinical trials may be interpreted by the FDA in different ways than we interpret it; the FDA may not agree with our regulatory approval strategies or components of our filings for our products, including our clinical trial designs, conduct and methodologies and, for ALKS 5461, evidence of efficacy and adequacy of bridging to buprenorphine; clinical development activities may not be completed on time or at all; the results of our clinical development activities may not be positive, or predictive of real - world results or of results in subsequent clinical trials; regulatory submissions may not occur or be submitted in a timely manner; the company and its licensees may not be able to continue to successfully commercialize their products; there may be a reduction in payment rate or reimbursement for the company's products or an increase in the company's financial obligations to governmental payers; the FDA or regulatory authorities outside the U.S. may make adverse decisions regarding the company's products; the company's products may prove difficult to manufacture, be precluded from commercialization by the proprietary rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse; and those risks and uncertainties described under the heading «Risk Factors» in the company's most recent Annual Report on Form 10 - K and in subsequent filings made by the company with the U.S. Securities and Exchange Commission («SEC»), which are available on the SEC's website at www.sec.gov.

It pointed to the continued presence of fragile fixed - income market liquidity as a key vulnerability in the overall financial system, while it repeats the risks of a sharp increase in long - term interest rates, stress from emerging markets like China and prolonged weakness in commodity prices.

He says the actions of central banks «attempting to spark economic growth» are «severely punishing the world's savers and creating incentives to reach for yield, pushing investors into less liquid asset classes and increased levels of risk, with potentially dangerous financial and economic consequences.»

«Pipeline construction would negatively affect TransCanada's business risk profile through increased project execution risk, and would likely put pressure on financial metrics.»

How many employees and managers of the world's largest financial institutions were aware of the increased risks their firms were taking on in the run up to the latest crisis?

While retaining its ratings on the financial institutions S&P noted «the risk of a sharp correction in property prices has further increased.»

New Zealand's booming housing prices are now 45.4 % above the previous market peak of late 2007, and officials warn the rapid increases pose a risk to financial stability.

We believe that higher financial risk stemming from management's willingness to increase leverage for acquisitions is mitigated by its disciplined approach — as demonstrated by the unsuccessful bid for Casey's in 2010 and resistance to a higher bid for Statoil.

Among the factors that could cause actual results to differ materially are the following: (1) worldwide economic, political, and capital markets conditions and other factors beyond the Company's control, including natural and other disasters or climate change affecting the operations of the Company or its customers and suppliers; (2) the Company's credit ratings and its cost of capital; (3) competitive conditions and customer preferences; (4) foreign currency exchange rates and fluctuations in those rates; (5) the timing and market acceptance of new product offerings; (6) the availability and cost of purchased components, compounds, raw materials and energy (including oil and natural gas and their derivatives) due to shortages, increased demand or supply interruptions (including those caused by natural and other disasters and other events); (7) the impact of acquisitions, strategic alliances, divestitures, and other unusual events resulting from portfolio management actions and other evolving business strategies, and possible organizational restructuring; (8) generating fewer productivity improvements than estimated; (9) unanticipated problems or delays with the phased implementation of a global enterprise resource planning (ERP) system, or security breaches and other disruptions to the Company's information technology infrastructure; (10) financial market risks that may affect the Company's funding obligations under defined benefit pension and postretirement plans; and (11) legal proceedings, including significant developments that could occur in the legal and regulatory proceedings described in the Company's Annual Report on Form 10 - K for the year ended Dec. 31, 2017, and any subsequent quarterly reports on Form 10 - Q (the «Reports»).

When your company can pay you an adequate salary, that's the time for you to diversify by spreading your financial risk to increase your payoff potential.

Hawks like Germany and the Netherlands now want a commitment to end these buys, arguing that they have also increased risks to financial instability and allowed other countries to put off necessary reforms.

«The question from a financial stability point of view is whether or not those measures, to the extent they encourage more credit and more investment, may not buy some more growth today, but increase the risk of some disruption in growth further down the road,» Carolyn Wilkins, the Bank of Canada's senior deputy governor, said at least week's press conference.

These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).

Chapter 1 concludes that although economic benefits of monetary ease are becoming more evident in some economies, market and liquidity risks have increased to levels that could compromise financial stability if left unaddressed.

More broadly, global trade has slowed and financial stability risks have increased — with the recent market turmoil partly reflecting lower confidence in the effectiveness of policies.

Description: The April 2018 Global Financial Stability Report (GFSR) finds that short - term risks to financial stability have increased somewhat since the previFinancial Stability Report (GFSR) finds that short - term risks to financial stability have increased somewhat since the previfinancial stability have increased somewhat since the previous GFSR.

The April 2018 Global Financial Stability Report (GFSR) finds that short - term risks to financial stability have increased somewhat since the previFinancial Stability Report (GFSR) finds that short - term risks to financial stability have increased somewhat since the previfinancial stability have increased somewhat since the previous GFSR.

So this first line of explanation stresses the factors that are common to all financial bubbles — in particular the combination of cheap credit and a general increase in the appetite for risk.

Authorities could also, in principle, adjust macroprudential tools to dampen financial cycles — tightening them when leverage is building up and risk taking is increasing, and easing those requirements when that cycle turns.

This has been the situation in Canada for the past seven years, as reflected in increasing levels of household indebtedness and elevated house prices — although, as I'll discuss later, regulatory measures have been used to mitigate the resulting financial system risks (Chart 2).3

The Dodd - Frank bill, which was passed in 2010 in response to the financial crisis, aimed to decrease various risks across the financial system and increase regulatory oversight to prevent such a meltdown from happening again.

Current political and financial uncertainty surrounding the European Union may increase market volatility and the economic risk of investing in companies in Europe.

Accordingly, the Governing Council agreed that acting at this time was consistent both with the Bank's primary mission — the pursuit of its inflation target — as well as helping to manage financial stability risks, even if there could be some increase in financial vulnerabilities in the process.

The GFSR begins with the observation that «Risks to financial stability have increased since the April 2012 GFSR, as confidence in the global financial system have become very fragile.»

The increase in the ties between national financial systems, the greater sophistication of financial markets and financial market instruments allow risks to be shared more broadly and capital to flow to where the returns are expected to be the highest.

So do the increase in the mobility of saving and investment; the increase in the desired exposure to foreign assets (the reduction in home bias); the financial market innovation that allows for better diversification and risk sharing; and the differentials in the pace of technology adoption or workplace practices that give rise to varying productivity trends across countries.

Jan 25, 2016: Since the 2008 financial crisis, institutional investors have sought new methods of managing risk and increasing returns while maintaining exposure to equities.

A company with negative working capital (more liabilities than assets) is generally seen as being in financial risk for increased debt (which may lead to bankruptcy).

«Negative publicity or public opinion resulting from these matters may increase the risk of reputational harm to our business, which can impact our ability to keep and attract customers, our ability to attract and retain qualified team members, result in the loss of revenue, or have other material adverse effects on our results of operations and financial condition.»

The Report, which follows 9 months of investigation, finds that the banks do not prioritize financial consumer protection, fairness and product suitability and as a result there is an increased risk of mis - selling to consumers and of bank employees breaching market conduct obligations.

This white paper looks at the period of the increased volatility in the financial markets leading up to and on November 8th and provides valuable insights into internal workings of risk parity strategies during periods of heightened volatility.

The shadow banking industry plays a critical role in meeting rising credit demand in the United States, and although it's been argued that shadow banking's disintermediation can increase economic efficiency, its operation outside of traditional banking regulations raises concerns over the systemic risk it may pose to the financial system.

In Australia, the lifting of interest rates and credit controls, and increased competition from foreign banks, contributed to a surge in credit growth, and a substantial increase in risk taking in the financial sector, and in the community generally.

Locking money up for a long time period — more than 10 years — is a bad idea because it reduces access to an investment and increases risk, according to many financial advisors.

That said, some experts point out that financial institutions might adopt their own private and closed blockchain systems, which could result in less security and increased risk of criminal inside jobs.